

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method of treating or preventing hearing loss associated with epilepsy at 4 kHz or 8 kHz in a patient, the method comprising administering to the patient a composition comprising vinpocetine, or a derivative thereof in an amount effective to antagonize inhibit alterations in the auditory brainstem response (ABR) waves, and a pharmaceutically acceptable vehicle.

2. (Currently Amended) The method of claim 1, comprising treating alterations of retro-cochlear origin, characterized by the inhibition of the alterations of the alteration of amplitudes and latencies of the later waves of the ABR.

3. (Currently Amended) The method of claim 1, comprising treating hearing loss alterations of retro-cochlear origin, characterized by an increase in the auditory threshold induced by pentylenetetrazole or 4-aminopyridine the inhibition of the alteration of latencies of later waves of the ABR.

4. (Currently Amended) The method of claim 1, comprising administering vinpocetine or a derivative thereof in an amount effective to inhibit the epileptic cortical activity for the ictal and post-ictal periods.

5. (Currently Amended) The method of claim 1, wherein the vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.

6. (Currently Amended) The method of claim 2, wherein the vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.

7. (Currently Amended) The method of claim 3, wherein the vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.

8. (Currently Amended) The method of claim 4, wherein the vincristine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.